PRGO — Perrigo Company plc stock price, charts and financials

QT39Perrigo Company plc

Perrigo Company plc (NYSE: PRGO) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
10.78
+0.10+0.94%
PRGOQT39Perrigo Company plc·NYSE
10.78+0.94%
Earnings
Up 0.9% — Reported earnings — EPS beat by 40%, revenue missed by 6%.
High confidence
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-13.11Insider Own1.22%Shs Outstand138.37MPerf Week4.66%
Market Cap1.49BForward P/E4.55EPS next Y2.37Insider Trans0.00%Shs Float137.64MPerf Month-2.80%
Enterprise Value4.94BPEG-EPS next Q-Inst Own-Short Float16.66%Perf Quarter-5.36%
Income-1.82BP/S0.36EPS this Y116.17%Inst Trans-Short Ratio7.22Perf Half Y-24.72%
Sales4.18BP/B0.60EPS next Y11.79%ROA-22.77%Short Interest22.93MPerf YTD-22.56%
Book/sh18.06P/C4.18EPS next 5Y8.15%ROE-50.65%52W High27.16 -60.31%Perf Year-59.53%
Cash/sh2.58P/FCF12.99EPS past 3/5Y-ROIC3.37%52W Low9.23 16.79%Perf 3Y-70.51%
Dividend Est.1.16 (10.76%)EV/EBITDA-Sales past 3/5Y-1.51% 0.79%Gross Margin34.17%Volatility3.40% 4.41%Perf 5Y-77.11%
Dividend TTM1.16 (10.76%)EV/Sales1.18EPS Y/Y TTM-948.80%Oper. Margin5.67%ATR (14)0.48Perf 10Y-88.35%
Dividend Ex-DateAug 28, 2026Quick Ratio1.59Sales Y/Y TTM-4.46%Profit Margin-43.50%RSI (14)55.54Recom2.64
Dividend Gr. 3/5Y3.71% 5.21%Current Ratio2.72EPS Q/Q-28.33%SMA203.79%Beta0.54Target Price36.20
Payout-8.73%Debt/Eq1.35Sales Q/Q-7.18%SMA502.33%Rel Volume0.85Prev Close10.68
Employees8,100LT Debt/Eq1.33EarningsAug 05SMA200-15.48%Avg Volume3.37MPrice10.78
IPO DateDec 17, 1991Option/ShortYes / YesEPS/Sales Surpr.40.17% -6.38%Net Debt/EBITDA-2.78Volume2,859,674Change0.94%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-06-25DowngradeJP MorganOverweightNeutral
Nov-06-25ReiteratedCanaccord GenuityBuy$40$20
Oct-27-25ReiteratedJefferiesHold$30$23
Aug-07-25ReiteratedCanaccord GenuityBuy$40
Jan-14-25DowngradeArgusBuyHold
Jan-06-25DowngradePiper SandlerOverweightNeutral
Sep-23-24DowngradeJefferiesBuyHold$30
Jun-13-24ReiteratedPiper SandlerOverweight$39$36
Apr-08-24ReiteratedPiper SandlerOverweight$37$39
Nov-17-23InitiatedPiper Sandler$37
Latest News
Jul-30-26
Jul-30-2608:30AM
Jul-29-26
Jul-22-26
Jul-14-26
Jun-30-26
Jun-25-26
Jun-15-26
Jun-12-26
Jun-10-26
Company

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,1784,2534,3734,6564,4524,1394,0883,8704,732
Cost of Goods Sold Incl. D&A2,7502,7592,8312,9752,9962,7232,5932,4362,900
Gross Profit1,4281,4951,5431,6801,4551,4161,4951,4341,832
Selling, General and Administrative Excl. Other3765271,1131,2751,2101,1111,1091,0971,126
Research and Development9495112123123122122119219
Other Operating Expense72352920513144-227-1435
Operating Income23734311315279410265175237
Interest Expense165163188174156125128127129
Unusual Expense
Non-Operating Income (Expense)-1,787-1,479-614-62-27-132100183
Net Income Before Taxes-1,715-1,298-81-8-1392596148291
Income Taxes7810480-4-8390-38-11160
Consolidated Net Income-1,817-1,425-172-13-141-69-163146131
Net Income From Continuing Operations-1,791-1,402-161-4-131-13144159131
Net Income-1,817-1,425-172-13-141-69-163146131
EPS (Recurring)-13.11-10.29-1.25-0.09-0.97-0.98-1.191.070.95
EPS (Basic, Before Extraordinaries)-13.11-10.29-1.25-0.09-0.97-0.98-1.191.070.95
EPS (Diluted)-13.11-10.29-1.25-0.09-0.97-0.98-1.191.070.95
EBITDA-1,239-798433525356696518662906
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio48.2840.79
Price To Sales Ratio0.360.450.810.931.031.261.491.821.13
Gross Margin34.1835.1535.2836.0832.6834.2136.5737.0538.72
Operating Margin5.678.062.583.261.779.916.484.525.01
Net Margin-43.49-33.51-3.93-0.28-3.17-1.67-3.993.772.77
Shares Outstanding139139137135135134136136138
Market Capitalization1,4981,9353,5224,3444,6025,2136,0827,0265,348
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$31.31$25.07$18.84$12.61$6.37 Close Price0.00K101.21K202.41K303.62K404.82KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Winterman Matthew JohnEVP, Supply, Ops, StrategyJul 08 '26Option Exercise10.5217,503184,13115,660Jul 09
Khoury RobertoEVP and President of CSCIJul 08 '26Option Exercise10.527377,75314,498Jul 09
Parker Geoffrey M.DirectorJun 12 '26Option Exercise10.9997610,72633,686Jun 16
Alford Bradley ADirectorJun 12 '26Option Exercise10.9997610,72645,934Jun 16
Lockwood-Taylor Patrickother: Former CEO and directorJun 05 '26Option Exercise10.8325,230273,241136,076Jun 09
Khoury RobertoEVP and President of CSCIJun 05 '26Option Exercise10.8317,902193,87817,433Jun 08
Willis RobertEVP & CHROJun 05 '26Option Exercise10.833,44137,26652,365Jun 08
Lennox AbigailEVP and CSOJun 05 '26Option Exercise10.833,82341,4036,603Jun 08
Bezerra Eduardo GuaritaEVP & Chief Financial OfficerJun 05 '26Option Exercise10.839,17599,36586,935Jun 08
Ball DavidEVP & CBDOJun 05 '26Option Exercise10.832,86731,0507,784Jun 08
Atkinson CharlesEVP, General Counsel & Sec.Jun 05 '26Option Exercise10.836,69072,4537,690Jun 08
O'Connor DonalDirectorMay 14 '26Option Exercise10.847,30579,18637,942May 15
Parker Geoffrey M.DirectorMay 14 '26Option Exercise10.847,30579,18636,217May 15
Brown Julia MDirectorMay 14 '26Option Exercise10.847,30579,18615,339May 15
Manzone AlbertDirectorMay 14 '26Option Exercise10.847,30579,18619,860May 15
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.